Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

A2 Review article, Literature review, Systematic review

Internal Authors/Editors

Publication Details

List of Authors: Anna Wawruszak, Joanna Kalafut, Estera Okon, Jakub Czapinski, Marta Halasa, Alicja Przybyszewska, Paulina Miziak, Karolina Okla, Adolfo Rivero-Muller, Andrzej Stepulak
Publisher: MDPI
Publication year: 2019
Journal: Cancers
Journal acronym: Cancers
Volume number: 11
Issue number: 2
Number of pages: 31
ISSN: 2072-6694


Histone deacetylase inhibitors (HDIs) are a group of potent epigenetic drugs which have been investigated for their therapeutic potential in various clinical disorders, including hematological malignancies and solid tumors. Currently, several HDIs are already in clinical use and many more are on clinical trials. HDIs have shown efficacy to inhibit initiation and progression of cancer cells. Nevertheless, both pro-invasive and anti-invasive activities of HDIs have been reported, questioning their impact in carcinogenesis. The aim of this review is to compile and discuss the most recent findings on the effect of HDIs on the epithelial-mesenchymal transition (EMT) process in human cancers. We have summarized the impact of HDIs on epithelial (E-cadherin, beta-catenin) and mesenchymal (N-cadherin, vimentin) markers, EMT activators (TWIST, SNAIL, SLUG, SMAD, ZEB), as well as morphology, migration and invasion potential of cancer cells. We further discuss the use of HDIs as monotherapy or in combination with existing or novel anti-neoplastic drugs in relation to changes in EMT.


Cadherin, catenin, EMT, HDAC, HDI, MET, Vimentin

Last updated on 2020-07-04 at 04:20